CLINICAL TRIALS
ATA-200 Dose-escalation Gene Therapy Trial in Patients with LGMDR5
This is a multicenter Phase 1b assessing the safety and tolerability of 2 doses of ATA-200 for the treatment of LGMDR5.
Atamyo Therapeutics clinicaltrials.gov
Sponsor:
Atamyo Therapeutics
Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD) (GRASP-01-001)
Limb-Girdle Muscular Dystrophy (LGMD) is a group of over 30 rare genetic disorders causing progressive weakness in the shoulder and hip muscles. Collectively, LGMDs are among the four most common muscular dystrophies. Project 1 aims to define key clinical phenotypes using standard outcome assessments to accelerate therapy development.
Sponsor:
Virginia Commonwealth University
Recent Articles
May 11 - 15, 2026
March 9, 2026
February 16, 2026